Announcements

Announcements

Paul G. Allen Frontiers Group [to 20 Jul 2019]
https://alleninstitute.org/what-we-do/frontiers-group/news-press/
News
These neurons are tied to one of multiple sclerosis’ most dramatic effects: Brain shrinkage
July 17, 2019
A new study identifies a type of brain cell that withers away in late stages of the disease

 

BMGF – Gates Foundation [to 20 Jul 2019]
http://www.gatesfoundation.org/Media-Center/Press-Releases
No new digest content identified.

 

Bill & Melinda Gates Medical Research Institute [to 20 Jul 2019]
https://www.gatesmri.org/
The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world’s poorest people
No new digest content identified.

 

CARB-X [to 20 Jul 2019]
https://carb-x.org/
CARB-X is a non-profit public-private partnership dedicated to accelerating antibacterial research to tackle the global rising threat of drug-resistant bacteria.
No new digest content identified.

 

CEPI – Coalition for Epidemic Preparedness Innovations [to 20 Jul 2019]
http://cepi.net/
17 July 2019
CEPI awards funding agreement worth up to US$9.5 million to Colorado State University to develop a human vaccine against Rift Valley fever
Oslo, Norway, July 17, 2019—The Coalition for Epidemic Preparedness Innovations (CEPI) and Colorado State University (CSU) today announce a partnering agreement to advance the development of a vaccine candidate against Rift Valley fever (RVF) virus. With support from the European Union’s (EU’s) Horizon 2020 programme, CEPI will provide up to US$9.5 million for manufacturing and preclinical studies to assess a single-dose vaccine candidate (DDVax) against RVF. First identified in 1931 during an investigation into an outbreak among sheep on a farm in the Rift Valley of Kenya, this potentially fatal virus is found across Africa and is now emerging in the Middle East.
DDVax is a second generation RVF vaccine, which was designed after researchers identified and removed the key genes of the virus that allowed it to cause disease. Removal of these genes also stops the virus from replicating in mosquitoes—a known vector that spreads the disease in animals and in humans—therefore blocking this potential route of transmission. The vaccine stimulates the body’s immune system to generate neutralising antibodies against the RVF virus. It also likely generates a significant cellular immune response that can kill infected cells…

 

Clinton Health Access Initiative, Inc. (CHAI) [to 20 Jul 2019]
https://clintonhealthaccess.org/about/
Published July 15th, 2019
CHAI Financials: 2018

 

EDCTP [to 20 Jul 2019]
http://www.edctp.org/
The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials
Latest news
19 July 2019
African High Commissioners and Ambassadors in Pretoria met EDCTP
African High Commissioners and Ambassadors from 18 countries accredited to South Africa met with EDCTP in Pretoria on 11 July 2019. The meeting was hosted by the Mozambique High Commission. The objective of the meeting was to inform the Ambassadors about the EDCTP activities in sub-Saharan Africa. EDCTP aims to increase the political and financial support of African countries for clinical research and the development of the associated research capacity in Africa, as part of the common pursuit of the Sustainable Development Goals.…

 

Emory Vaccine Center [to 20 Jul 2019]
http://www.vaccines.emory.edu/
No new digest content identified.

 

European Medicines Agency [to 20 Jul 2019]
http://www.ema.europa.eu/ema/
News and press releases
No new digest content identified.

 

European Vaccine Initiative [to 20 Jul 2019]
http://www.euvaccine.eu/news-events
No new digest content identified.

 

FDA [to 20 Jul 2019]
https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/default.htm
No new digest content identified.

 

Fondation Merieux [to 20 Jul 2019]
http://www.fondation-merieux.org/
No new digest content identified.

 

Gavi [to 20 Jul 2019]
https://www.gavi.org/
No new digest content identified.

 

GHIT Fund [to 20 Jul 2019]
https://www.ghitfund.org/newsroom/press
GHIT was set up in 2012 with the aim of developing new tools to tackle infectious diseases that devastate the world’s poorest people. Other funders include six Japanese pharmaceutical
No new digest content identified.

 

Global Fund [to 20 Jul 2019]
https://www.theglobalfund.org/en/news/
No new digest content identified.

 

Hilleman Laboratories [to 20 Jul 2019]
http://www.hillemanlabs.org/
No new digest content identified.

 

Human Vaccines Project [to 20 Jul 2019]
http://www.humanvaccinesproject.org/media/press-releases/
No new digest content identified.

 

IAVI [to 20 Jul 2019]
https://www.iavi.org/newsroom
No new digest content identified.

 

International Coalition of Medicines Regulatory Authorities (ICMRA)
http://www.icmra.info/drupal/en/news
No new digest content identified.

 

IFFIm
http://www.iffim.org/library/news/press-releases/
18 July 2019
IFFIm issues NOK600 million Vaccine Bonds [click link to review “restricted access library note]
Funding will support CEPI’s development of new vaccines to prevent deadly diseases.
London, 18 July 2019 – The International Finance Facility for Immunisation (IFFIm) today issued NOK600,000,000 Zero Coupon Notes to help finance research and development of new vaccines by the Coalition for Epidemic Preparedness Innovation (CEPI). CEPI is a public private initiative that accelerates development of vaccines against emerging infectious diseases and enables equitable access to these vaccines for affected populations during outbreaks.
The vaccine bonds will frontload a NOK600 million pledge from the Government of Norway to Gavi in support of CEPI .
Today’s issuance was lead managed by Skandinaviska Enskilda Banken (SEB) and the Toronto-Dominion Bank. The issuance, which will mature on 15 March 2025, has a reoffer price of 93.892, 2bps through mid-swaps in NOK…

 

IFRC [to 20 Jul 2019]
http://media.ifrc.org/ifrc/news/press-releases/
Selected Press Releases, Announcements
Asia Pacific, Bangladesh
Bangladesh: Severe flooding puts more than 4 million people at risk of food insecurity and disease
Dhaka/Kuala Lumpur/Geneva, 19 July 2019 – Days of severe rains have battered the northern and southeastern part of Bangladesh, putting more than 4 million people at risk of food insecurity and disease. Floods and landslides have damaged roads and vital …
19 July 2019

Asia Pacific, DPRK
DPR Korea: Malnutrition and disease on the rise as drought ruins early harvest
Beijing/Kuala Lumpur/Geneva, 18 July 2019 –-An early season drought in the Democratic People’s Republic of Korea (DPRK) has cut by half the expected production of a critical harvest, increasing pressure on highly vulnerable groups across the country. T …
18 July 2019

 

IVAC [to 20 Jul 2019]
https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html
No new digest content identified.

 

IVI [to 20 Jul 2019]
http://www.ivi.int/
IVI News & Announcements
No new digest content identified.

 

JEE Alliance [to 20 Jul 2019]
https://www.jeealliance.org/
Selected News and Events
No new digest content identified.

 

MSF/Médecins Sans Frontières [to 20 Jul 2019]
http://www.msf.org/
Selected News; Project Updates, Reports
DRC Ebola outbreaks
Crisis update – July 2019

Colombia
The uncertain lives of Venezuelan migrants on the Colombian border
Project Update 17 Jul 2019

HIV/AIDS
Fight is not over as AIDS deaths remain high
Press Release 16 Jul 2019

Public health
Eight things we’ve learned from MSF operational research projects
Interview 16 Jul 2019

 

NIH [to 20 Jul 2019]
http://www.nih.gov/news-events/news-releases
July 15, 2019
NIH and partners to launch HIV vaccine efficacy trial in the Americas and Europe
— Study will enroll men who have sex with men and transgender people; complementary study in women is ongoing.
The National Institutes of Health and partners today announced plans to conduct a Phase 3 HIV vaccine efficacy trial at multiple clinical research sites in North America, South America and Europe. The trial, called HPX3002/HVTN 706 or Mosaico, will assess whether an investigational vaccine regimen designed to induce immune responses against a variety of global HIV strains can safely and effectively prevent HIV acquisition among men who have sex with men and transgender people. A complementary study in women called HPX2008/HVTN 705 or Imbokodo that launched in 2017 in five southern African countries is ongoing.
Mosaico is sponsored by Janssen Vaccines & Prevention, B.V., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, with funding support from NIH’s National Institute of Allergy and Infectious Diseases (NIAID). The HIV Vaccine Trials Network (HVTN), headquartered at the Fred Hutchinson Cancer Research Center in Seattle, is facilitating the implementation of the study. Additional partners providing support include the U.S. Army Medical Research and Development Command (USAMRDC). The public-private partnership’s plans for Mosaico will be described in more detail at the 10th IAS Conference on HIV Science (IAS 2019) in Mexico City.
This Phase 3 efficacy study will enroll 3,800 HIV-negative men and transgender people aged 18 to 60 years who have sex with men and/or transgender people. It is anticipated to open for enrollment at clinical research sites in the United States later this year. In addition, clinical research sites in Argentina, Brazil, Italy, Mexico, Peru, Poland and Spain will participate in the study…

 

PATH [to 20 Jul 2019]
https://www.path.org/media-center/
July 16, 2019 by PATH
PATH welcomes Abayomi Sule, Rachel Sibande, and Lisa Anderson to its board of directors
July 16, 2019 by PATH
PATH’s board of directors are pleased to welcome Dr. Abayomi Sule, Dr. Rachel Sibande, and Lisa Pigott Anderson to the board. Dr. Sule brings extensive experience in healthcare management, consulting, and advising local and international organizations, as well as a passion for healthcare innovations and transparency. Dr. Sibande enhances the board’s knowledge in public health, food security, and disaster management through her leadership in leveraging data for international development projects. Ms. Anderson brings decades of executive leadership and volunteer experience with charitable foundations and NGOs and a demonstrated passion to improve maternal and women’s health in low-resource settings.

 

Sabin Vaccine Institute [to 20 Jul 2019]
http://www.sabin.org/updates/pressreleases
No new digest content identified.

 

UNAIDS [to 20 Jul 2019]
http://www.unaids.org/en
Selected Press Releases/Reports/Statements
15 July 2019
Pan-African Parliament calls for increased domestic resources for HIV and health in Africa
25 July 2019
Indonesia commits to piloting PrEP

 

UNICEF [to 20 Jul 2019]
https://www.unicef.org/media/press-releases
Selected Statements, Press Releases, Reports
Press release
‘Transformative shift’ in support for families of young children urgently needed worldwide – UNICEF
The United Nations Children’s Fund has released new recommendations on family-friendly policies including paid parental leave, breastfeeding support, childcare and child benefits
18/07/2019

News note
Unwanted, exploited and abused: Tens of thousands of children in Al-Hol camp and several parts of Syria in limbo amid dire humanitarian needs
UNICEF calls for improved humanitarian access and protection of children including re-integration into local communities and safe return to home countries
17/07/2019
16/07/2019

Press release
Geneva Palais briefing note on the impact of the Ebola outbreak on children in the Democratic Republic of the Congo
This is a summary of what was said by Marixie Mercado, UNICEF spokesperson in Geneva – to whom quoted text may be attributed – at today’s press briefing at the Palais des Nations in Geneva.
16/07/2019
[See Milestones above for detail]

Statement
Remarks from UNICEF Deputy Executive Director Omar Abdi at the High-Level Event on the Response and Preparedness for the Ebola Outbreak in the Democratic Republic of the Congo
15/07/2019
[See Milestones above for detail]

Press release
20 million children missed out on lifesaving measles, diphtheria and tetanus vaccines in 2018
New estimates find dangerous stagnation of global vaccination rates, due to conflict, inequality and complacency
15/07/2019
[See Milestones above for detail]

Press release
Mass campaign to vaccinate over 3 million children against polio kicks off in Venezuela
14/07/2019
[See Milestones above for detail]

 

Vaccination Acceptance Research Network (VARN) [to 20 Jul 2019]
https://vaccineacceptance.org/news.html#header1-2r
No new digest content identified.

 

Vaccine Confidence Project [to 20 Jul 2019]
http://www.vaccineconfidence.org/
Posted on 19 Jul, 2019
Peter Piot reaction to Ebola outbreak in DRC being declared a Public Health Emergency of International Concern 17 July 2019

 

Vaccine Education Center – Children’s Hospital of Philadelphia [to 20 Jul 2019]
http://www.chop.edu/centers-programs/vaccine-education-center
No new digest content identified.

 

Wellcome Trust [to 20 Jul 2019]
https://wellcome.ac.uk/news
News | 18 July 2019
New funding to boost global research capacity in humanities and social science
We’ve launched two new calls to fund international exchange programmes and research development activities for humanities and social science researchers around the world – the International Exchange Programmes and Research Development Awards.

 

The Wistar Institute [to 20 Jul 2019]
https://www.wistar.org/news/press-releases
No new digest content identified.

 

World Organisation for Animal Health (OIE) [to 20 Jul 2019]
http://www.oie.int/en/for-the-media/press-releases/2019/
No new digest content identified.

::::::

BIO [to 20 Jul 2019]
https://www.bio.org/insights/press-release
No new digest content identified.

 

DCVMN – Developing Country Vaccine Manufacturers Network [to 20 Jul 2019]
http://www.dcvmn.org/
No new digest content identified.

 

IFPMA [to 20 Jul 2019]
http://www.ifpma.org/resources/news-releases/
No new digest content identified.

 

PhRMA [to 20 Jul 2019]
http://www.phrma.org/press-room
No new digest content identified.

 

Industry Watch [to 20 Jul 2019]
:: Boehringer Ingelheim Acquires AMAL Therapeutics, Significantly Enriching Its Cancer Immunology Portfolio with Novel Cancer Vaccines Platform
:: Acquisition adds key platform supporting Boehringer Ingelheim’s focus on patients with difficult-to-treat gastrointestinal and lung cancers
:: AMAL’s first-in-class proprietary KISIMA® platform leverages peptide/protein-based vaccination technology
: AMAL will remain at the campus of the University of Geneva in Switzerland and operate as a subsidiary within Boehringer Ingelheim

July 15, 2019 INGELHEIM AM RHEIN, Germany & GENEVA– Boehringer Ingelheim today announced its acquisition of all shares of AMAL Therapeutics SA, a private Swiss biotechnology company focused on cancer immunotherapy and advancing first-in-class therapeutic cancer vaccines derived from its technology platform KISIMA. AMAL’s lead vaccine ATP128 is currently developed for stage IV colorectal cancer and is slated to begin first-in-human trials later this month. Boehringer Ingelheim plans to develop new therapies by combining assets from its cancer immunology portfolio with AMAL’s proprietary KISIMA immunization platform.

“Acquiring AMAL is part of Boehringer Ingelheim’s long-term strategy to enhance our existing position as an innovator of novel cancer therapies, including immuno-oncology treatments, which leverage cutting-edge scientific discoveries and their applications,” said Michel Pairet, member of Boehringer Ingelheim’s Board of Managing Directors with responsibility for the company’s Innovation Unit. “We want to pioneer new paradigms of biology-based care for cancer patients, and the technologies and expertise developed at AMAL are critical to our efforts.”

The total transaction could amount up to EUR 325 million, and is comprised of an upfront payment as well as contingent clinical, development and regulatory milestones plus up to EUR 100 million if certain commercial milestones are hit…